Indian J Pharm Close
 

Figure 4: PQDS reduced the mRNA level of proto-oncogenes. (a) The expression of proto-oncogenes (c-myc, c-fos, and c-jun) was evaluated by RT-PCR. Total RNA was extracted from cultured VSMCs at 48 h after treatment (for PCR amplification primers see Table 1). (b) The mRNA level of proto-oncogenes was quantified relative to the GAPDH level. The x-axis represents the drug doses used. Data was quantified from three independent experiments. #P < 0.05 compared to the control group; *P < 0.05 compared to the AngII treatment group; ^P < 0.05 compared to the diltiazem treatment group

Figure 4: PQDS reduced the mRNA level of proto-oncogenes. (a) The expression of proto-oncogenes (c-myc, c-fos, and c-jun) was evaluated by RT-PCR. Total RNA was extracted from cultured VSMCs at 48 h after treatment (for PCR amplification primers see Table 1). (b) The mRNA level of proto-oncogenes was quantified relative to the GAPDH level. The x-axis represents the drug doses used. Data was quantified from three independent experiments. #<i>P</i> < 0.05 compared to the control group; *<i>P</i> < 0.05 compared to the AngII treatment group; ^<i>P</i> < 0.05 compared to the diltiazem treatment group